There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Humacyte (HUMA – Research Report), Rallybio (RLYB – Research Report) and Avidity Biosciences (RNA – Research Report) with bullish sentiments.
Humacyte (HUMA)
In a report issued on May 10, Josh Jennings from TD Cowen maintained a Buy rating on Humacyte, with a price target of $6.00. The company’s shares closed last Monday at $5.39.
According to TipRanks.com, Jennings is a 4-star analyst with an average return of
Humacyte has an analyst consensus of Strong Buy, with a price target consensus of $8.25, implying a 74.1% upside from current levels. In a report released today, Benchmark Co. also maintained a Buy rating on the stock with a $15.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Rallybio (RLYB)
In a report released today, Ritu Baral from TD Cowen initiated coverage with a Buy rating on Rallybio. The company’s shares closed last Monday at $1.82, close to its 52-week low of $1.23.
According to TipRanks.com, Baral is a 4-star analyst with an average return of
Currently, the analyst consensus on Rallybio is a Strong Buy with an average price target of $12.00, implying a 552.2% upside from current levels. In a report issued on May 10, JMP Securities also reiterated a Buy rating on the stock with a $8.00 price target.
Avidity Biosciences (RNA)
In a report issued on May 8, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Avidity Biosciences, with a price target of $38.00. The company’s shares closed last Monday at $26.43, close to its 52-week high of $27.66.
According to TipRanks.com, Schwartz is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avidity Biosciences with a $43.20 average price target, which is a 65.9% upside from current levels. In a report issued on May 3, Bank of America Securities also initiated coverage with a Buy rating on the stock with a $40.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HUMA:
